Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)

The standing updates came aft Amgen Inc. (NASDAQ:AMGN) reported its fiscal Q4 and afloat twelvemonth 2025 results connected February 3, announcing beardown show successful 2025 with double-digit maturation successful revenues and EPS. Total revenues for fiscal Q4 roseate 9% to $9.9 cardinal compared to the anterior twelvemonth period, with merchandise income increasing 7%, driven by 10% measurement growth. Total revenues for the afloat twelvemonth reached $36.8 billion, up 10% compared to the aforesaid 4th past year.

Amgen Inc. (NASDAQ:AMGN) further reported that merchandise income grew 10%, driven by 13% measurement growth, partially offset by 3% little nett selling price. 18 of the company’s products attained grounds income for the afloat year, portion 14 products exceeded 1 cardinal dollars successful yearly sales. Amgen Inc. (NASDAQ:AMGN) expects full revenues successful the $37.0 cardinal to $38.4 cardinal scope for the afloat twelvemonth 2026.

Amgen Inc. (NASDAQ:AMGN) is simply a biotechnology institution that discovers, develops, manufactures, and markets quality therapeutics. It delivers caller therapies for patients with analyzable cancers, particularly successful areas with important unmet needs.

While we admit the imaginable of AMGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.